|
Celebrex, Bextra likely to benefit from FDA review.(MERCHANDISING)(Brief Article) |
|
|
|
|
Written by Admin
|
|
Wednesday, 10 October 2007 |
Celebrex, Bextra likely to benefit from FDA review.(MERCHANDISING)(Brief Article)NEW YORK -- The conclusion by a Food and Drug Administration panel that the benefits of COX-2 inhibitors outweigh their risks is likely to lead to higher sales of two of them--Bextra and Celebrex. That probability was revealed in research conducted by NOP World Health. A provider of information to the health care industry, NOP World Health conducted its research after the panel issued its recommendations earlier this year.
It found that general and family physicians particularly anticipated increasing their Bextra prescriptions. And internists, rheumatologists and ... Source: http://findarticles.com |
